Article Text

Download PDFPDF
Report from the 21st meeting of the European Society of Gynaecological Oncology (ESGO 2019)
  1. Nicolò Bizzarri1,
  2. Zoia Razumova2,
  3. Ilker Selcuk3,
  4. Nadja Taumberger4,
  5. Tanja Nikolova5,
  6. Christina Fotopoulou6,
  7. Elzbieta Van der Steen-Banasik7,
  8. Annamaria Ferrero8 and
  9. Kamil Zalewski9
  1. 1 Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy
  2. 2 Division of Obstetrics and Gynaecology, Department of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden
  3. 3 Gynaecologic Oncology, University of Health Sciences, Ankara City Hospital, Maternity Hospital, Ankara, Turkey
  4. 4 Division of Gynaecology, Medical University of Graz, Graz, Austria
  5. 5 Klinikum Mittelbaden, Academic Teaching Hospital of Heidelberg University, Baden-Baden, Germany
  6. 6 Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, UK
  7. 7 Radiation Oncology, RtG, Arnhem, The Netherlands
  8. 8 Academic Department Gynaecology and Obstetrics, Mauriziano Hospital, Torino, Italy
  9. 9 Gynaecologic Oncology, Holycross Cancer Centre, Kielce, Poland
  1. Correspondence to Dr Nicolò Bizzarri, Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome 00168, Italy; nicolo.bizzarri{at}yahoo.com

Abstract

This is a report from the 21st Meeting of the European Society of Gynaecological Oncology (ESGO 2019) held in Athens, Greece, November 2–5, 2019. The conference offered state of the art educational sessions, and oral and poster abstract presentations. The general sessions throughout the meeting focused not only on prevention, screening, diagnosis, treatment, and translational research but also on emerging trends. Current innovations in gynecological cancers were also discussed. The new rare tumor guidelines project, a joint initiative with the ESGO-Gynecologic Cancer InterGroup, was officially presented for the first time. Moreover, other developments achieved with other societies, such as the European Society for Medical Oncology for ovarian cancer, the European Federation for Colposcopy for cervical cancer prevention and screening, and the European Society for Pediatric Oncology for gynecologic cancers in adolescents, were presented. Here we highlight the key results of the latest gynecological cancer trials that were presented for the first time at ESGO 2019 and added great value to this prestigious scientific congress.

  • ovarian cancer
  • cervical cancer
  • vulvar and vaginal cancer
  • radiation oncology
  • surgical oncology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @ilkerselcukmd

  • Contributors NB: conceptualization, data curation, methodology, and writing original draft. ZR: data curation, methodology, writing original draft, review, and editing. IS: data curation, methodology, and writing original draft. NT: data curation, methodology, and writing original draft. TN: review and editing. CF: data curation, methodology, review, and editing. EVDS: data curation, methodology, review, and editing. AF: data curation, methodology, review, and editing, KZ: conceptualization, data curation, methodology, writing original draft, review, and editing.

  • Funding The work was funded through the European Network of Young Gynaecological Oncologists (ENYGO) budget grant that was provided by the European Society of Gynaecological Oncology (ESGO).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.